Last reviewed · How we verify
NCT07439484: PRECISE
Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial
NA trial testing Actigraphy in Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8 in 20 participants. Not yet recruiting.
1 March 2027
Quick facts
| Lead sponsor | Jonsson Comprehensive Cancer Center |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 20 |
| Start date | 1 March 2026 |
| Primary completion | 1 March 2027 |
| Estimated completion | 1 March 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Actigraphy
- Biospecimen Collection — full drug profile →
- Educational Intervention
- Educational Intervention
- Electronic Health Record Review
- Exercise Intervention
- Internet-Based Intervention
- Physical Performance Testing
- Survey Administration
Conditions studied
- Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8 — all drugs for Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8 →
- Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8 — all drugs for Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8 →
- Clinical Stage I Gastric Cancer AJCC v8 — all drugs for Clinical Stage I Gastric Cancer AJCC v8 →
- Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 — all drugs for Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 →
Sponsor
Jonsson Comprehensive Cancer Center — full company profile →
Who can join
18 and older, any sex, with Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8 or Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial tests an individually tailored, supervised, remote exercise intervention to improve physical function for stage I-III gastroesophageal cancer survivors. Modern treatments for gastroesophageal cancer are effective at treating the cancer but are often aggressive, can be difficult for patients to tolerate, and can lead to significant debilitation and a loss of independence. Exercise is one promising intervention that could improve physical function in patients with gastroesophageal cancer after finishing systemic treatment. Home based exercise interventions in patients with cancer during and after chemotherapy can improve fatigue and function. An individually tailored, supervised, remote exercise intervention may improve physical function for stage I-III gastroesophageal cancer survivors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07439484
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Actigraphy
Trials testing the same drug.
- NCT07192380 — Shift Hours' Impact on Fatigue and Tracking of Eye Dynamics · NA · not yet recruiting
- NCT06104280 — Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implica · recruiting
- NCT06816225 — Association Between Sleep and Psychomotor Development in Early Childhood · recruiting
- NCT05378932 — Impact of Dysregulation of Core Body Temperature on Sleep in Patients With Hypohidrotic Ectodermal Dysplasia · NA · completed
- NCT04569643 — Periodic Limb Movement Syndrome in Patients With Cerebral Small Vessel Disease. · unknown
Other Jonsson Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
- NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
- NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
- NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07439484 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07439484.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing